• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Bivalirudin during and post-percutaneous coronary intervention reduces bleeding and mortality compared to heparin monotherapy

byNeel MistryandTeddy Guo
December 6, 2022
in Cardiology, Chronic Disease, Neurology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Bivalirudin during percutaneous coronary intervention plus high-dose infusion after demonstrated decreased all-cause mortality compared to heparin monotherapy.

2. Risk of major bleeding was marginally greater in the heparin monotherapy group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Percutaneous coronary intervention (PCI) is used as first-line treatment in patients with ST-segment elevation myocardial infarction (STEMI). Although studies show that bivalirudin, a direct-acting thrombin inhibitor, may be used to reduce bleeding, there has been conflicting evidence with differences in methodology. This randomized trial aimed to compare the safety and efficacy of bivalirudin versus heparin monotherapy in patients with ST-segment elevated myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). The primary outcome was a composite of all-cause mortality and major bleeding, as defined by Bleeding Academic Research Consortium (BARC) types 3-5. Patients were randomly assigned to either intervention group and received bivalirudin with a post-PCI high-dose infusion or unfractionated heparin monotherapy. According to study results, patients randomized to bivalirudin demonstrated significantly decreased all-cause mortality and major bleeding at 30 days. This study was strengthened by a large sample size, adding to its validity.

Click to read the study in The Lancet

Relevant Reading: Bivalirudin versus Heparin Monotherapy in Myocardial Infarction

RELATED REPORTS

Early screening for emotional and cognitive issues may improve psychiatric outcomes for stroke patients

Impaired lipoprotein cholesterol ratio is associated with cognitive impairment in patients with stroke

Personalized visual perceptual learning digital therapy may improve vision post-stroke

In-depth [randomized-controlled trial]: Between Feb 14, 2019, and Apr 7, 2022, 6016 patients were assigned from 87 clinical sites in China. Included were patients undergoing primary percutaneous coronary intervention (PCI) within 48 hours of STEMI who were not on any anticoagulants, fibrinolytic therapy, or glycoprotein IIb/IIIa inhibitors. Altogether, 6016 patients (3009 to bivalirudin plus high-dose infusion after PCI and 3007 to heparin monotherapy) were included in the final analysis. The primary outcome composite of all-cause mortality and major bleeding at 30 days was significantly decreased in the bivalirudin group compared to the heparin monotherapy group (3.06% vs. 4.39%, respectively, hazard ratio [HR] 0.69, 95% confidence interval [CI] 0.53-0.91, p=0.0070). Although stent thrombosis was more common in the heparin group (n=33, 1.10%) than bivalirudin (n=11, 0.37%), no significant differences occurred concerning reinfarction, stroke, or target vessel revascularization. Findings from this study suggest that treatment with bivalirudin plus high-dose infusion post-PCI may reduce mortality and major bleeding in patients with recent STEMI.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: acute myocardial infarctionBivalirudinbleedingbleeding riskcardiovascular diseasecardiovascular mortalitygastrointestinal bleedingheparinmyocardial infarctionpercutaneous coronary interventionpercutaneous coronary intervention (PCI)STEMIstroke
Previous Post

#VisualAbstract: Continuation of renin–angiotensin system inhibitors does not impact disease progression in those with advanced chronic kidney disease

Next Post

Supraphysiological perioperative oxygen associated with worse outcomes

RelatedReports

Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults
Neurology

Early screening for emotional and cognitive issues may improve psychiatric outcomes for stroke patients

June 20, 2025
Quick Take: Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial
Chronic Disease

Impaired lipoprotein cholesterol ratio is associated with cognitive impairment in patients with stroke

June 4, 2025
Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults
Chronic Disease

Personalized visual perceptual learning digital therapy may improve vision post-stroke

May 30, 2025
Stroke expansion following intra-arterial therapy may explain worse outcomes
Emergency

Delayed alteplase has clinical benefits in posterior circulation stroke outcomes

May 30, 2025
Next Post
Delays in surgical intervention do not increase odds of appendiceal perforation

Supraphysiological perioperative oxygen associated with worse outcomes

#VisualAbstract: Double sequential external defibrillation and vector-change defibrillation improve outcomes in patients with refractory ventricular fibrillation

#VisualAbstract: Double sequential external defibrillation and vector-change defibrillation improve outcomes in patients with refractory ventricular fibrillation

ACP offers recommendations to improve the ACA, patient care

Parent decision making in poor-prognosis childhood cancer may extend beyond values and preferences

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Weighted vests and resistance training confer similar outcomes for bone density in the elderly
  • Breast cancer survivors may have a lower risk of Alzheimer’s dementia
  • Evaluating scar outcomes in pediatric burn patients following skin grafting 
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.